Depressive Disorder News and Research

RSS

Short-duration psychedelic therapy shows promise for major depression treatment

A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.

17 Feb 2026

Simple wrist-worn device enables early detection of depression relapse

Could a smart watch act as an early‑warning system for depression relapse? New research from McMaster University suggests that disruptions in a person's sleep and daily activity routine, as detected through a simple wrist-worn device, can signal when there is increased risk of relapsing into major depression.

11 Feb 2026

Brain connectivity fingerprints differ in major depressive disorder

Major depressive disorder (MDD) is a debilitating condition that affects more than 246 million people worldwide, yet scientists have struggled to identify consistent brain markers that could improve diagnosis and treatment.

5 Feb 2026

King’s researchers help transform UK mental health research infrastructure

King’s researchers will help transform mental health data, clinical trials and industry partnerships as part of the UK Government’s Mental Health Goals programme.

30 Jan 2026

Research reveals dual impact of brain stimulation on people with depression and anxiety

Research investigating the effects of transcranial direct current stimulation (tDCS) on individuals with depression and comorbid anxiety reveals a dual impact of this noninvasive form of brain stimulation.

29 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

New medical LLM detects depression in women via WhatsApp audio analysis

A new medical large language model (LLM) achieved over 91 percent accuracy in identifying female participants diagnosed with major depressive disorder after analyzing a short WhatsApp audio recording where participants described their week, according to a study published January 21, 2026 in the open-access journal PLOS Mental Health by Victor H. O. Otani, from Santa Casa de São Paulo School of Medical Sciences and Infinity Doctors Inc., Brazil, and colleagues.

22 Jan 2026

Vagus nerve stimulation shows lasting benefit in treatment-resistant depression

Findings reveal that vagus nerve stimulation leads to lasting benefits in treatment-resistant depression, improving function and quality of life over two years.

16 Jan 2026

What makes depression apps safe, effective, and trustworthy?

The study identifies 28 key criteria for assessing depression apps, emphasizing safety and clinical validity to enhance digital mental health interventions.

15 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Elevated neutrophil-to-lymphocyte ratio linked to depression and suicide risk

An elevated neutrophil-to-lymphocyte ratio (NLR) is significantly associated with increased risk of depressive disorder (DD) and may also correlate with suicide risk among individuals with DD, according to a systematic review and meta-analysis published in the November issue of Harvard Review of Psychiatry, part of the Lippincott portfolio from Wolters Kluwer.

6 Jan 2026

Researchers identify a distinct immuno-inflammatory biomarker across major psychiatric disorders

Individuals with psychiatric disorders exhibiting seemingly similar symptoms often respond very differently to the same treatment, suggesting that distinct biological processes are at work beneath the surface of similar clinical presentations.

11 Dec 2025

Global study reveals massive hidden health burden from violence against women and children

Sexual violence against children and intimate partner violence against women are two of the most devastating yet persistently underrecognized global health challenges and rank among the top risks for mortality and morbidity worldwide, according to research published in The Lancet today.

9 Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

8 Dec 2025

Young Australians are staying on antidepressants for longer than ever

Long-term antidepressant use in Australia increased steadily between 2014 and 2023, with the largest relative rise seen among adolescents and young adults aged 10 to 24 years. Treatment duration also lengthened over time, while apparent dose reduction efforts remained limited, raising concerns about deprescribing practices.

7 Dec 2025

Short-term nitrous oxide treatment could benefit patients with major depressive disorder

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the University of Birmingham has found.

1 Dec 2025

Moderate coffee intake linked to slower biological aging in people with severe mental illness

Drinking a maximum of 3-4 cups of coffee a day may slow the 'biological' ageing of people with severe mental illness, by lengthening their telomeres-indicators of cellular ageing-and giving them the equivalent of 5 extra biological years, compared with non-coffee drinkers, finds research published in the open access journal BMJ Mental Health.

25 Nov 2025